PharmaMar announces that it has received payment of $100 million from Jazz Pharmaceuticals for the approval of ZepzelcaTM (lurbinectedin) in the U.S.
(World News Austria)

PharmaMar announces that it has received payment of $100 million from Jazz Pharmaceuticals for the approval of ZepzelcaTM (lurbinectedin) in the U.S.  PharmaMar could receive up to an additional US $150 million when full approval is achieved.  On June 15th, 2020 lurbinectedin was approved by the FDA for the treatment of adult patients with metastatic Small Cell Lung Cancer (SCLC) with disease progression.  Jazz Pharmaceuticals to launch lurbinectedin in the U.S. in July. Madrid, June 29th, 2020.- PharmaMar (MSE:PHM) has today announced that it has received payment of $100 million from Jazz Pharmaceuticals, corresponding to the first part of the regulatory milestones, for the approval of...